Ind Swift Laboratories Fair Value
Ind Swift Laboratories fair value. Ind Swift Laboratories (INDSWFTLAB) average fair value is ₹163.71 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹385.75 (-57.56%), fair value range ₹34.55–₹465.31. Check Ind Swift Laboratories market worth to track the company's total market size over time.
Fair Value Analysis Export
INDSWFTLAB Fair Value vs Current Price — Valuation Summary
INDSWFTLAB average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. Explore INDSWFTLAB investment value to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
INDSWFTLAB Fair Value Analysis — Data Sources & Coverage
Ind Swift Laboratories financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit Ind Swift Laboratories share price chart.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
INDSWFTLAB vs Healthcare Sector Peers — P/E, P/B & Market Cap
Ind Swift Laboratories P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Syngene International | SYNGENE | 68.69 | 3.13 | ₹15,000 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.